分析
2026年8月30日•1分で読めます
Domestic NOAC leader Rixiana faces supply strain ahead of November patent expiry
Rixiana (edoxaban) shows signs of supply pressure across all dosages as its Korean patent expires in November, prompting close monitoring of the market.
分析
2026年8月30日•1分で読めます
Supply Prices of Hydrasexan Antidiarrheal Raised Effective July 1
Korean Aebot and Samjin Pharma have sharply increased the supply price of the pediatric and adult antidiarrheal Hydrasexan due to raw‑material costs and exchange‑rate shifts.